Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PECS 112

Next Previous
X
Search
Drug Profile

PECS 112

Alternative Names: PECS-112

Latest Information Update: 08 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Universidade Federal do Rio Grande do Sul; University of Sao Paulo; Yissum Research Development Company
  • Developer Phytecs
  • Class Cannabinoids; Fluorine compounds; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 20 Sep 2023 PECS 112 is available for licensing as of 20 Sep 2023. http://www.phytecs.com/licensing/
  • 20 Sep 2023 Phytecs has filed for patent protection of proprietary botanical compounds and formulations (Phytecs Pipeline, September 2023)
  • 20 Sep 2023 Phytecs has pending compound structure claims and use claims in the Australia, China, Canada, Europe, Hong Kong, Japan, and Mexico on its lead F-CBD variants (Phytecs Pipeline, September 2023).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top